2018
Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/&mgr;l
Kong CY, Sigel K, Criss SD, Sheehan DF, Triplette M, Silverberg MJ, Henschke CI, Justice A, Braithwaite RS, Wisnivesky J, Crothers K. Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/&mgr;l. AIDS 2018, 32: 1333-1342. PMID: 29683843, PMCID: PMC5991188, DOI: 10.1097/qad.0000000000001818.Peer-Reviewed Original ResearchConceptsLow-dose computed tomographyLung cancer screeningCD4 cell countMedicaid Services criteriaCancer screeningLung cancerMortality reductionCell countLDCT examinationsAnnual low-dose computed tomographyUninfected individualsLung cancer mortality reductionVeterans Aging Cohort StudyCancer mortality reductionAntiretroviral therapy adherenceAging Cohort StudyLung cancer mortalityCells/Lung Cancer Policy ModelMultiple national organizationsAlternative screening strategiesBase-case analysisHIV cohortCohort studyFormer smokers
2008
Drug Toxicity, HIV Progression, or Comorbidity of Aging: Does Tipranavir Use Increase the Risk of Intracranial Hemorrhage?
Justice AC, Zingmond DS, Gordon KS, Fultz SL, Goulet JL, King JT, Bravata DM, Valdez H, Kraft M, Mattocks KM, Team T. Drug Toxicity, HIV Progression, or Comorbidity of Aging: Does Tipranavir Use Increase the Risk of Intracranial Hemorrhage? Clinical Infectious Diseases 2008, 47: 1226-1230. PMID: 18831696, DOI: 10.1086/592302.Peer-Reviewed Original Research